Ambit Biosciences presents data evaluating FLT3 inhibitor in AML at the 51st ASH meeting

Ambit Biosciences Corporation announced today that there will be multiple presentations evaluating AC220, a novel second generation FLT3 inhibitor, in AML at the 51st American Society of Hematology Annual Meeting (ASH) to be held in New Orleans, LA ,December 5-8, 2009. An oral presentation will highlight results from an ongoing clinical Phase I monotherapy safety study in adults with acute myeloid leukemia (AML). Additionally, non-clinical data will be presented evaluating the effect of AC220 monotherapy and in combination with chemotherapy.

"AML continues to be a disease with a significant unmet medical need and new therapies are urgently needed," said M. Scott Salka, Chief Executive Officer of Ambit Biosciences. "The Phase I clinical data we've seen for AC220 in AML are extremely encouraging and supports the further development of this highly selective second-generation FLT3 inhibitor."

Data Highlights for AC220 include:

ORAL PRESENTATIONS

Abstract #636

AC220, a Potent, Selective, Second Generation FLT3 Receptor Tyrosine Kinase (RTK) Inhibitor, in a First-in-Human (FIH) Phase 1 AML Study

Presented by: Jorge Cortes, MD

Session Name: Acute Myeloid Leukemia - Therapy, excluding Transplantation II

Date: Monday, December 7, 2009, 5:45pm (session: 4:30 - 6:00pm), Morial Convention Center Room 343-345

POSTER PRESENTATIONS

Abstract# 2053

AC220 - A FLT3 Inhibitor, Increases Survival in Two Genotypically Distinct FLT3-ITD Models of Acute Myeloid Leukemia and Provides Sustained Protection Following Chronic Administration

Session Name: Acute Myeloid Leukemia - Therapy, excluding Transplantation II

Sunday, December 6, 2009, 6:00 - 8:00pm, Hall E, Poster Board II-45

Abstract#: 2052

AC220, a Potent and Specific FLT3 Inhibitor, Enhances the Cytotoxic Effects of Chemotherapeutic Agents in Cell Culture and in Mouse Tumor Xenograft

Session Name: Acute Myeloid Leukemia - Therapy, excluding Transplantation II

Sunday, December 6, 2009, 6:00 PM - 8:00 PM, Hall E, Poster Board II-44

Source:

Ambit Biosciences Corporation

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
Scientists develop a marker for therapy response in acute myeloid leukemia